First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growth First quarter reported diluted earnings per share ("EPS") of $2.24, ...
Danaher (NYSE:DHR) reported first-quarter 2026 sales of $6.0 billion, with core revenue up 0.5% year over year as strength in ...
Q1 2026 Earnings Call April 21, 2026 8:00 AM EDTCompany ParticipantsRachel VatnsdalRainer Blair - President, CEO ...
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, ...
Only stockholders of record at the close of business on April 1, 2026, the record date, will be entitled to vote at the Annual Meeting.
The Atlas Load Reset™ training addresses the structural patterns that keep growing businesses dependent on their founders, offering a diagnostic framework built from 34 years of high-stakes litigation ...
ESTABLISHING a national precision medicine strategy, anchored by a clearly defined coordinating body tops the priority list ...
Antimicrobial resistance to common bacteria is rising worldwide, eroding the effectiveness of last-line antibiotics against ...
This Clinical Chemistry and Laboratory Medicine review examines a central challenge in precision medicine: whether medical ...
For many families, eight years of uncertainty meant repeated specialist visits, inconclusive genetic tests and the growing ...
Regeneron Pharmaceuticals plans to expand its pipeline into radiopharmaceutical therapies through an up to $4.3 billion collaboration with Telix Pharmaceuticals to co-develop and co-commercialize ...
Philips receives FDA 510(k) clearance for Verida, the world’s first AI-powered detector-based spectral CT*, advancing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results